

Helpful Hints for Ordering the clonoSEQ Assay

Questions? Contact Adaptive Clinical Services
P: 888 552 8988 | F: 866 623 4408
clinicalservices@adaptivebiotech.com

clonoseq.com



SPECIMEN PREPARATION

Review Requirements

- ✓ Guidance for sending specimens can be found in the Specimen Requirements document here: adaptivebiotech.com/specimens

Provide Ample Material

- ✓ If ordering more than one Clonality Test (i.e. B-cell **and** T-cell) include double the sample material requested in the Specimen Requirements document.

Label w/ 2 Unique Identifiers

- ✓ Each specimen must be labeled with **2 unique patient identifiers**. These identifiers must match the patient information you entered on the Test Requisition Form (TRF).



TEST REQUISITION FORM (TRF)

Complete



✓ FILL OUT SPECIMEN FIELDS

Fully complete the Specimen Information section of the TRF, especially the "collection date." These fields are not required to save and print a TRF, but **they are required prior to sending a specimen.**

Verify



✓ VERIFY INSURANCE INFORMATION HASN'T CHANGED

If you previously provided a patient's insurance details, they will automatically appear when you start a new TRF. Verify this information is correct before saving and printing the TRF.

Sign



✓ PROVIDE SIGNED & DATED TRF

A physical copy of your TRF must be signed, dated, and sent to Adaptive before a sample can be processed.

Request



✓ PROVIDE COMPLETE PATHOLOGY REPORT

If you would like assistance from Adaptive to request a pathology sample, **send a copy of the patient's complete pathology report with the signed and dated TRF** to Clinical Services.



Required fields are highlighted in yellow on a printed TRF as a reminder to complete them before sending. **TRFs with missing or incorrect information will delay ordering and the delivery of patient results.**

clonoSEQ®

Copyright © 2018 Adaptive Biotechnologies Corp.
All rights reserved.
PM-US-cSEQ-0112 | MRK-00195-1

clonoSEQ is an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies for use in B-cell acute lymphoblastic leukemia and multiple myeloma patients to detect and monitor measurable residual disease (MRD) in bone marrow samples. clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. clonoSEQ is available by prescription only. For important information about the FDA-cleared uses of clonoSEQ, including test limitations, visit clonoseq.com/technical-summary.

Adaptive